Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Lung Diseases 1Locally Advanced Non-small Cell Lung Cancer 1Liver Neoplasms 1Liver Diseases 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Dexamethasone 45Bortezomib 19Lenalidomide 18Calcium Dobesilate 18Melphalan 16Cyclophosphamide 11pomalidomide 10daratumumab 9elotuzumab 8carfilzomib 8pembrolizumab 6ixazomib 6fludarabine phosphate 6dexamethasone acetate 6fludarabine 5dexamethasone 21-phosphate 5Filgrastim 5venetoclax 4selinexor 4auricularum 4Thalidomide 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4liposomal doxorubicin 3Whole-Body Irradiation 3Vorinostat 3Nivolumab 3Mycophenolic Acid 3Leukapheresis 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Multiple Myeloma × Immunotherapy × Clear all
NCT05950113 2024-05-01

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡